Advances in Antifungal Development: Discovery of New Drugs and Drug Repurposing
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Acknowledgments
Conflicts of Interest
References
- Roemer, T.; Krysan, D.J. Antifungal Drug Development: Challenges, Unmet Clinical Needs, and New Approaches. Cold Spring Harb. Perspect. Med. 2014, 4, a019703. [Google Scholar] [CrossRef] [PubMed]
- Houšť, J.; Spížek, J.; Havlíček, V. Antifungal Drugs. Metabolites 2020, 10, 106. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Nami, S.; Aghebati-Maleki, A.; Morovati, H.; Aghebati-Maleki, L. Current antifungal drugs and immunotherapeutic approaches as promising strategies to treatment of fungal diseases. Biomed. Pharmacother. 2019, 110, 857–868. [Google Scholar] [CrossRef]
- Nett, J.E.; Andes, D.R. Antifungal Agents: Spectrum of Activity, Pharmacology, and Clinical Indications. Infect. Dis. Clin. N. Am. 2016, 30, 51–83. [Google Scholar] [CrossRef] [PubMed]
- Rajendran, R.; Mowat, E.; Jones, B.; Williams, C.; Ramage, G. Prior in vitro exposure to voriconazole confers resistance to amphotericin B in Aspergillus fumigatus biofilms. Int. J. Antimicrob. Agents 2015, 46, 342–345. [Google Scholar] [CrossRef] [Green Version]
- Vazquez, J.A.; Arganoza, M.T.; Boikov, D.; Yoon, S.; Sobel, J.D.; Akins, R.A. Stable Phenotypic Resistance of Candida Species to Amphotericin B Conferred by Preexposure to Subinhibitory Levels of Azoles. J. Clin. Microbiol. 1998, 36, 2690–2695. [Google Scholar] [CrossRef] [Green Version]
- Delattin, N.; Cammue, B.P.; Thevissen, K. Reactive oxygen species-inducing antifungal agents and their activity against fungal biofilms. Future Med. Chem. 2014, 6, 77–90. [Google Scholar] [CrossRef]
- Bowyer, P.; Denning, D.W. Environmental fungicides and triazole resistance in Aspergillus. Pest Manag. Sci. 2014, 70, 173–178. [Google Scholar] [CrossRef]
- Centers for Disease Control and Prevention (U.S.). Antibiotic Resistance Threats in the United States, 2019; Department of Health and Human Services, CDC: Atlanta, GA, USA, 2019. Available online: https://stacks.cdc.gov/view/cdc/82532 (accessed on 3 June 2022).
- Bongomin, F.; Gago, S.; Oladele, R.O.; Denning, D.W. Global and Multi-National Prevalence of Fungal Diseases—Estimate Precision. J. Fungi 2017, 3, 57. [Google Scholar] [CrossRef]
- Brown, G.D.; Denning, D.W.; Gow, N.A.R.; Levitz, S.M.; Netea, M.G.; White, T.C. Hidden Killers: Human Fungal Infections. Sci. Transl. Med. 2012, 4, 165rv13. [Google Scholar] [CrossRef] [Green Version]
- Gonçalves, B.; Ferreira, C.; Alves, C.T.; Henriques, M.; Azeredo, J.; Silva, S. Vulvovaginal candidiasis: Epidemiology, microbiology and risk factors. Crit. Rev. Microbiol. 2016, 42, 905–927. [Google Scholar] [CrossRef] [Green Version]
- Centers for Disease Control and Prevention (U.S.). Invasive Candidiasis Statistics. Available online: https://www.cdc.gov/fungal/diseases/candidiasis/invasive/statistics.html (accessed on 3 June 2022).
- Hamill, R.J. Amphotericin B Formulations: A Comparative Review of Efficacy and Toxicity. Drugs 2013, 73, 919–934. [Google Scholar] [CrossRef] [PubMed]
- Marena, G.D.; Ramos, M.A.d.S.; Bauab, T.M.; Chorilli, M. A Critical Review of Analytical Methods for Quantification of Amphotericin B in Biological Samples and Pharmaceutical Formulations. Crit. Rev. Anal. Chem. 2022, 52, 555–576. [Google Scholar] [CrossRef] [PubMed]
- Sousa, F.; Ferreira, D.; Reis, S.; Costa, P. Current Insights on Antifungal Therapy: Novel Nanotechnology Approaches for Drug Delivery Systems and New Drugs from Natural Sources. Pharmaceuticals 2020, 13, 248. [Google Scholar] [CrossRef] [PubMed]
- Bouz, G.; Doležal, M. Advances in Antifungal Drug Development: An Up-to-Date Mini Review. Pharmaceuticals 2021, 14, 1312. [Google Scholar] [CrossRef]
- Rachini, A.; Pietrella, D.; Lupo, P.; Torosantucci, A.; Chiani, P.; Bromuro, C.; Proietti, C.; Bistoni, F.; Cassone, A.; Vecchiarelli, A. An Anti-Beta-Glucan Monoclonal Antibody Inhibits Growth and Capsule Formation of Cryptococcus neoformans In Vitro and Exerts Therapeutic, Anticryptococcal Activity In Vivo. Infect. Immun. 2007, 75, 5085–5094. [Google Scholar] [CrossRef] [Green Version]
- Di Mambro, T.; Vanzolini, T.; Bruscolini, P.; Perez-Gaviro, S.; Marra, E.; Roscilli, G.; Bianchi, M.; Fraternale, A.; Schiavano, G.F.; Canonico, B.; et al. A new humanized antibody is effective against pathogenic fungi in vitro. Sci. Rep. 2021, 11, 19500. [Google Scholar] [CrossRef]
- Vetvicka, V.; Vannucci, L.; Sima, P.; Richter, J. Beta Glucan: Supplement or Drug? From Laboratory to Clinical Trials. Molecules 2019, 24, 1251. [Google Scholar] [CrossRef] [Green Version]
- Kaminski, K.; Skora, M.; Krzyściak, P.; Stączek, S.; Zdybicka-Barabas, A.; Cytryńska, M. Synthesis and Study of Antifungal Properties of New Cationic Beta-Glucan Derivatives. Pharmaceuticals 2021, 14, 838. [Google Scholar] [CrossRef]
- Yagüe, N.; Gómez-Delgado, L.; Curto, M.Á.; Carvalho, V.S.D.; Moreno, M.B.; Pérez, P.; Ribas, J.C.; Cortés, J.C.G. Echinocandin Drugs Induce Differential Effects in Cytokinesis Progression and Cell Integrity. Pharmaceuticals 2021, 14, 1332. [Google Scholar] [CrossRef]
- Mendling, W.; Atef El Shazly, M.; Zhang, L. Clotrimazole for Vulvovaginal Candidosis: More Than 45 Years of Clinical Experience. Pharmaceuticals 2020, 13, 274. [Google Scholar] [CrossRef] [PubMed]
- Ogundeji, A.O.; Mjokane, N.; Folorunso, O.S.; Pohl, C.H.; Nyaga, M.M.; Sebolai, O.M. The Repurposing of Acetylsalicylic Acid as a Photosensitiser to Inactivate the Growth of Cryptococcal Cells. Pharmaceuticals 2021, 14, 404. [Google Scholar] [CrossRef]
- Stapleton, M.; Rhodes, L.E. Photosensitizers for photodynamic therapy of cutaneous disease. J. Dermatol. Treat. 2003, 14, 107–112. [Google Scholar] [CrossRef] [PubMed]
- Cosio, T.; Gaziano, R.; Zuccari, G.; Costanza, G.; Grelli, S.; Di Francesco, P.; Bianchi, L.; Campione, E. Retinoids in Fungal Infections: From Bench to Bedside. Pharmaceuticals 2021, 14, 962. [Google Scholar] [CrossRef] [PubMed]
- Rodríguez-Villar, K.; Hernández-Campos, A.; Yépez-Mulia, L.; Sainz-Espuñes, T.d.R.; Soria-Arteche, O.; Palacios-Espinosa, J.F.; Cortés-Benítez, F.; Leyte-Lugo, M.; Varela-Petrissans, B.; Quintana-Salazar, E.A.; et al. Design, Synthesis and Anticandidal Evaluation of Indazole and Pyrazole Derivatives. Pharmaceuticals 2021, 14, 176. [Google Scholar] [CrossRef] [PubMed]
- Kane, A.; Carter, D.A. Augmenting Azoles with Drug Synergy to Expand the Antifungal Toolbox. Pharmaceuticals 2022, 15, 482. [Google Scholar] [CrossRef] [PubMed]
- de Souza, L.C.d.S.V.; Alcântara, L.M.; de Macêdo-Sales, P.A.; Reis, N.F.; de Oliveira, D.S.; Machado, R.L.D.; Geraldo, R.B.; dos Santos, A.L.S.; Ferreira, V.F.; Gonzaga, D.T.G.; et al. Synthetic Derivatives against Wild-Type and Non-Wild-Type Sporothrix brasiliensis: In Vitro and In Silico Analyses. Pharmaceuticals 2022, 15, 55. [Google Scholar] [CrossRef]
- Cha, Y.; Erez, T.; Reynolds, I.J.; Kumar, D.; Ross, J.; Koytiger, G.; Kusko, R.; Zeskind, B.; Risso, S.; Kagan, E.; et al. Drug repurposing from the perspective of pharmaceutical companies. Br. J. Pharmacol. 2018, 175, 168–180. [Google Scholar] [CrossRef] [Green Version]
- Peyclit, L.; Yousfi, H.; Rolain, J.-M.; Bittar, F. Drug Repurposing in Medical Mycology: Identification of Compounds as Potential Antifungals to Overcome the Emergence of Multidrug-Resistant Fungi. Pharmaceuticals 2021, 14, 488. [Google Scholar] [CrossRef]
- Schloer, S.; Goretzko, J.; Rescher, U. Repurposing Antifungals for Host-Directed Antiviral Therapy? Pharmaceuticals 2022, 15, 212. [Google Scholar] [CrossRef]
- Vanier, M.; Millat, G. Niemann–Pick disease type C. Clin. Genet. 2003, 64, 269–281. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Côté, M.; Misasi, J.; Ren, T.; Bruchez, A.; Lee, K.; Filone, C.M.; Hensley, L.; Li, Q.; Ory, D.; Chandran, K.; et al. Small molecule inhibitors reveal Niemann–Pick C1 is essential for Ebola virus infection. Nature 2011, 477, 344–348. [Google Scholar] [CrossRef] [PubMed]
- Herbert, A.S.; Davidson, C.; Kuehne, A.I.; Bakken, R.; Braigen, S.Z.; Gunn, K.E.; Whelan, S.P.; Brummelkamp, T.R.; Twenhafel, N.A.; Chandran, K.; et al. Niemann-Pick C1 Is Essential for Ebolavirus Replication and Pathogenesis In Vivo. mBio 2015, 6, e00565-00515. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Schloer, S.; Goretzko, J.; Kühnl, A.; Brunotte, L.; Ludwig, S.; Rescher, U. The clinically licensed antifungal drug itraconazole inhibits influenza virus in vitro and in vivo. Emerg. Microbes Infect. 2019, 8, 80–93. [Google Scholar] [CrossRef] [Green Version]
- Karam, B.S.; Morris, R.S.; Bramante, C.T.; Puskarich, M.; Zolfaghari, E.J.; Lotfi-Emran, S.; Ingraham, N.E.; Charles, A.; Odde, D.J.; Tignanelli, C.J. mTOR inhibition in COVID-19: A commentary and review of efficacy in RNA viruses. J. Med. Virol. 2021, 93, 1843–1846. [Google Scholar] [CrossRef]
- Kuss-Duerkop, S.K.; Wang, J.; Mena, I.; White, K.; Metreveli, G.; Sakthivel, R.; Mata, M.A.; Muñoz-Moreno, R.; Chen, X.; Krammer, F.; et al. Influenza virus differentially activates mTORC1 and mTORC2 signaling to maximize late stage replication. PLoS Pathog. 2017, 13, e1006635. [Google Scholar] [CrossRef]
- Shing, B.; Balen, M.; Debnath, A. Evaluation of Amebicidal and Cysticidal Activities of Antifungal Drug Isavuconazonium Sulfate against Acanthamoeba T4 Strains. Pharmaceuticals 2021, 14, 1294. [Google Scholar] [CrossRef]
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Kim, J.H.; Cheng, L.W.; Land, K.M. Advances in Antifungal Development: Discovery of New Drugs and Drug Repurposing. Pharmaceuticals 2022, 15, 787. https://doi.org/10.3390/ph15070787
Kim JH, Cheng LW, Land KM. Advances in Antifungal Development: Discovery of New Drugs and Drug Repurposing. Pharmaceuticals. 2022; 15(7):787. https://doi.org/10.3390/ph15070787
Chicago/Turabian StyleKim, Jong H., Luisa W. Cheng, and Kirkwood M. Land. 2022. "Advances in Antifungal Development: Discovery of New Drugs and Drug Repurposing" Pharmaceuticals 15, no. 7: 787. https://doi.org/10.3390/ph15070787
APA StyleKim, J. H., Cheng, L. W., & Land, K. M. (2022). Advances in Antifungal Development: Discovery of New Drugs and Drug Repurposing. Pharmaceuticals, 15(7), 787. https://doi.org/10.3390/ph15070787